Cargando…
Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial
OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease in which patients are suffering various symptoms. Previous experimental studies suggested that herbal medicine Ukgansan (UGS) could be beneficial for PD. The aim of this pilot clinical trial was to evaluate the efficacy of UGS...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685812/ https://www.ncbi.nlm.nih.gov/pubmed/36438946 http://dx.doi.org/10.3389/fneur.2022.1025269 |
_version_ | 1784835601041719296 |
---|---|
author | Jin, Chul Cho, Ki-Ho Kwon, Seungwon Lee, Han-Gyul Kim, Tae-Hun Jung, Woo-Sang Moon, Sang-Kwan Cho, Seung-Yeon Kang, Byoung-Kab Park, Jung-Mi Park, Hi-Joon Ko, Chang-Nam |
author_facet | Jin, Chul Cho, Ki-Ho Kwon, Seungwon Lee, Han-Gyul Kim, Tae-Hun Jung, Woo-Sang Moon, Sang-Kwan Cho, Seung-Yeon Kang, Byoung-Kab Park, Jung-Mi Park, Hi-Joon Ko, Chang-Nam |
author_sort | Jin, Chul |
collection | PubMed |
description | OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease in which patients are suffering various symptoms. Previous experimental studies suggested that herbal medicine Ukgansan (UGS) could be beneficial for PD. The aim of this pilot clinical trial was to evaluate the efficacy of UGS for improving clinical symptoms in patients with PD. METHODS: Sixty patients with idiopathic PD were randomly assigned to receive either UGS plus acupuncture or acupuncture alone for 6 weeks. During the trial, all anti-parkinsonian medications were maintained. Subjects were evaluated for various clinical assessments of PD, including the Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39), until 12 weeks. RESULTS: In MDS-UPDRS between the groups, no significant time x group interaction was found. In the subgroup analysis of participants with anxiety, a significant time x group interaction was found in the PDQ-39 domain of mobility (P = 0.007), activities of daily living (P = 0.042), and the PDQ-39 summary index (P = 0.048). In addition, post-hoc analysis in participants with anxiety showed a significant decrease in the domains of mobility (P = 0.001) and activities of daily living (P = 0.013) at week 7. There were no adverse events associated with UGS. CONCLUSION: The additional administration of UGS has the potential to significantly improve the quality of life of PD patients with anxiety. In order to create more definitive evidence, clinical trials with more rigorous methodologies should be conducted in future. CLINICAL TRIAL REGISTRATION: http://cris.nih.go.kr, identifier: KCT0003444. |
format | Online Article Text |
id | pubmed-9685812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96858122022-11-25 Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial Jin, Chul Cho, Ki-Ho Kwon, Seungwon Lee, Han-Gyul Kim, Tae-Hun Jung, Woo-Sang Moon, Sang-Kwan Cho, Seung-Yeon Kang, Byoung-Kab Park, Jung-Mi Park, Hi-Joon Ko, Chang-Nam Front Neurol Neurology OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease in which patients are suffering various symptoms. Previous experimental studies suggested that herbal medicine Ukgansan (UGS) could be beneficial for PD. The aim of this pilot clinical trial was to evaluate the efficacy of UGS for improving clinical symptoms in patients with PD. METHODS: Sixty patients with idiopathic PD were randomly assigned to receive either UGS plus acupuncture or acupuncture alone for 6 weeks. During the trial, all anti-parkinsonian medications were maintained. Subjects were evaluated for various clinical assessments of PD, including the Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39), until 12 weeks. RESULTS: In MDS-UPDRS between the groups, no significant time x group interaction was found. In the subgroup analysis of participants with anxiety, a significant time x group interaction was found in the PDQ-39 domain of mobility (P = 0.007), activities of daily living (P = 0.042), and the PDQ-39 summary index (P = 0.048). In addition, post-hoc analysis in participants with anxiety showed a significant decrease in the domains of mobility (P = 0.001) and activities of daily living (P = 0.013) at week 7. There were no adverse events associated with UGS. CONCLUSION: The additional administration of UGS has the potential to significantly improve the quality of life of PD patients with anxiety. In order to create more definitive evidence, clinical trials with more rigorous methodologies should be conducted in future. CLINICAL TRIAL REGISTRATION: http://cris.nih.go.kr, identifier: KCT0003444. Frontiers Media S.A. 2022-11-10 /pmc/articles/PMC9685812/ /pubmed/36438946 http://dx.doi.org/10.3389/fneur.2022.1025269 Text en Copyright © 2022 Jin, Cho, Kwon, Lee, Kim, Jung, Moon, Cho, Kang, Park, Park and Ko. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Jin, Chul Cho, Ki-Ho Kwon, Seungwon Lee, Han-Gyul Kim, Tae-Hun Jung, Woo-Sang Moon, Sang-Kwan Cho, Seung-Yeon Kang, Byoung-Kab Park, Jung-Mi Park, Hi-Joon Ko, Chang-Nam Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title_full | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title_fullStr | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title_full_unstemmed | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title_short | Effectiveness and safety of herbal medicine Ukgansan for clinical symptoms in Parkinson's disease: A pilot, randomized, assessor-blinded clinical trial |
title_sort | effectiveness and safety of herbal medicine ukgansan for clinical symptoms in parkinson's disease: a pilot, randomized, assessor-blinded clinical trial |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685812/ https://www.ncbi.nlm.nih.gov/pubmed/36438946 http://dx.doi.org/10.3389/fneur.2022.1025269 |
work_keys_str_mv | AT jinchul effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT chokiho effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT kwonseungwon effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT leehangyul effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT kimtaehun effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT jungwoosang effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT moonsangkwan effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT choseungyeon effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT kangbyoungkab effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT parkjungmi effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT parkhijoon effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial AT kochangnam effectivenessandsafetyofherbalmedicineukgansanforclinicalsymptomsinparkinsonsdiseaseapilotrandomizedassessorblindedclinicaltrial |